{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:11:14Z","timestamp":1791252674311,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":1651,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"crossref","award":["#021039 and #701582"],"award-info":[{"award-number":["#021039 and #701582"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1093\/annonc\/mdv033","type":"journal-article","created":{"date-parts":[[2015,1,29]],"date-time":"2015-01-29T00:39:10Z","timestamp":1422491950000},"page":"973-981","source":"Crossref","is-referenced-by-count":45,"title":["A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent\/metastatic sarcomas\u2014NCIC-CTG IND 200"],"prefix":"10.1016","volume":"26","author":[{"given":"Q. S.-C.","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.O.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Alcindor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Goytain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Tozer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Knowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.B.","family":"Bramwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.K.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"Eisenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv033_bb0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/157488709787047585","article-title":"Molecular pathology of sarcomas","volume":"4","author":"Osuna","year":"2009","journal-title":"Rev Recent Clin Trials"},{"key":"10.1093\/annonc\/mdv033_bb0015","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1586\/14737140.8.6.939","article-title":"Molecular pathology and potential therapeutic targets in soft-tissue sarcoma","volume":"8","author":"Todd","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1093\/annonc\/mdv033_bb0020","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(02)09292-9","article-title":"Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial","volume":"359","author":"O'Sullivan","year":"2002","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdv033_bb0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/13577140220127512","article-title":"Adjuvant chemotherapy following complete resection of soft tissue sarcoma in adults: a clinical practice guideline","volume":"6","author":"Figueredo","year":"2002","journal-title":"Sarcoma"},{"key":"10.1093\/annonc\/mdv033_bb0030","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(12)70346-7","article-title":"Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial","volume":"13","author":"Woll","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv033_bb0035","series-title":"DeVita, Hellman, and Rosenberg's Cancer Principles and Practices of Oncology","author":"DeVita","year":"2008"},{"key":"10.1093\/annonc\/mdv033_bb0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/13577140310001607266","article-title":"Management of advanced adult soft tissue sarcoma","volume":"7","author":"Bramwell","year":"2003","journal-title":"Sarcoma"},{"key":"10.1093\/annonc\/mdv033_bb0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/47412","article-title":"The language of covalent histone modifications","volume":"403","author":"Strahl","year":"2000","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdv033_bb0050","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","article-title":"The epigenomics of cancer","volume":"128","author":"Jones","year":"2007","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdv033_bb0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1535-6108(03)00165-X","article-title":"Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?","volume":"4","author":"Johnstone","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdv033_bb0060","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1242\/jeb.01439","article-title":"Lifespan extension and elevated hsp gene expression in Drosophila caused by histone deacetylase inhibitors","volume":"208","author":"Zhao","year":"2005","journal-title":"J Exp Biol"},{"key":"10.1093\/annonc\/mdv033_bb0065","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1105166","article-title":"Stat3 dimerization regulated by reversible acetylation of a single lysine residue","volume":"307","author":"Yuan","year":"2005","journal-title":"Science"},{"key":"10.1093\/annonc\/mdv033_bb0070","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/sj.cdd.4401581","article-title":"Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells","volume":"12","author":"Roy","year":"2005","journal-title":"Cell Death Differ"},{"key":"10.1093\/annonc\/mdv033_bb0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2012.06.008","article-title":"Cancer genetics and epigenetics: two sides of the same coin?","volume":"22","author":"You","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdv033_bb0080","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nrc3486","article-title":"Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host","volume":"13","author":"Timp","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdv033_bb0085","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1038\/sj.onc.1202613","article-title":"SSX and the synovial-sarcoma-specific chimaeric protein SYT-SSX co-localize with the human Polycomb group complex","volume":"18","author":"Soulez","year":"1999","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdv033_bb0090","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.cub.2004.09.060","article-title":"SIR2 is required for polycomb silencing and is associated with an E(Z) histone methyltransferase complex","volume":"14","author":"Furuyama","year":"2004","journal-title":"Curr Biol"},{"key":"10.1093\/annonc\/mdv033_bb0095","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/70602","article-title":"Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation","volume":"23","author":"van der Vlag","year":"1999","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdv033_bb0100","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ccr.2012.01.010","article-title":"Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics","volume":"21","author":"Su","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdv033_bb0105","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.canlet.2004.10.030","article-title":"Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo","volume":"224","author":"Ito","year":"2005","journal-title":"Cancer Lett"},{"key":"10.1093\/annonc\/mdv033_bb0110","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1158\/0008-5472.CAN-08-0092","article-title":"Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma","volume":"68","author":"Lubieniecka","year":"2008","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv033_bb0115","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1038\/onc.2010.204","article-title":"EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor","volume":"29","author":"Su","year":"2010","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdv033_bb0120","doi-asserted-by":"crossref","first-page":"e1965","DOI":"10.1371\/journal.pone.0001965","article-title":"EWS\/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma","volume":"3","author":"Owen","year":"2008","journal-title":"PLoS One"},{"key":"10.1093\/annonc\/mdv033_bb0125","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1535-7163.MCT-05-0480","article-title":"Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells","volume":"5","author":"Hrzenjak","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdv033_bb0130","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/path.2434","article-title":"SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway","volume":"216","author":"Hrzenjak","year":"2008","journal-title":"J Pathol"},{"key":"10.1093\/annonc\/mdv033_bb0135","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/1535-7163.MCT-07-0560","article-title":"Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models","volume":"7","author":"Liu","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdv033_bb0140","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1158\/1535-7163.MCT-08-0985","article-title":"HDAC2 regulates chromatin plasticity and enhances DNA vulnerability","volume":"8","author":"Marchion","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdv033_bb0145","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/sj.bjc.6605293","article-title":"Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker","volume":"101","author":"Munster","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdv033_bb0150","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/bjc.2011.13","article-title":"Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours","volume":"104","author":"Razak","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdv033_bb0155","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1093\/annonc\/mdq784","article-title":"Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies","volume":"22","author":"Yong","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv033_bb0160","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1158\/1535-7163.MCT-11-0044","article-title":"Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue","volume":"10","author":"Novotny-Diermayr","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdv033_bb0165","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdv033_bb0170","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1128\/MCB.21.13.4110-4118.2001","article-title":"Pf1, a novel PHD zinc finger protein that links the TLE corepressor to the mSin3A-histone deacetylase complex","volume":"21","author":"Yochum","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1093\/annonc\/mdv033_bb0175","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00432-007-0227-8","article-title":"Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells","volume":"133","author":"Sonnemann","year":"2007","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1093\/annonc\/mdv033_bb0180","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1200\/JCO.2012.46.0147","article-title":"Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas","volume":"31","author":"Lagarde","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv033_bb0185","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1158\/1078-0432.CCR-09-0816","article-title":"NVP-BEZ235 as a new therapeutic option for sarcomas","volume":"16","author":"Manara","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv033_bb0190","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1091\/mbc.e08-12-1249","article-title":"ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery","volume":"20","author":"Jung","year":"2009","journal-title":"Mol Biol Cell"},{"key":"10.1093\/annonc\/mdv033_bb0195","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1158\/1535-7163.MCT-12-0015","article-title":"Targeting the PI3K\/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors","volume":"11","author":"Ghadimi","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdv033_bb0200","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1535-7163.MCT-08-1008","article-title":"Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor","volume":"8","author":"Zou","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdv033_bb0205","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4161\/cbt.12.6.16397","article-title":"Augmentation of NVP-BEZ235\u2032s anticancer activity against human lung cancer cells by blockage of autophagy","volume":"12","author":"Xu","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1093\/annonc\/mdv033_bb0210","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00109-011-0774-y","article-title":"Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma","volume":"89","author":"Mirzoeva","year":"2011","journal-title":"J Mol Med (Berl)"},{"key":"10.1093\/annonc\/mdv033_bb0215","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/bjc.2013.442","article-title":"A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group","volume":"109","author":"Cassier","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdv033_bb0220","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/modpathol.2011.157","article-title":"Histone deacetylase 1 and 2 in mesenchymal tumors","volume":"25","author":"Pacheco","year":"2012","journal-title":"Mod Pathol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419314966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419314966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/5\/973\/13705906\/mdv033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:48:23Z","timestamp":1624506503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419314966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0923753419314966"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv033","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}